| HS Code | 681696 |
| Brand Name | GANILEVER® Prefilled Syringe Inj. |
| Generic Name | Ganirelix Acetate |
| Dosage Form | Prefilled Syringe |
| Route Of Administration | Subcutaneous injection |
| Strength | 0.25 mg/0.5 mL |
| Indication | Prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation |
| Manufacturer | EMCURE Pharmaceuticals |
| Packaging | Single-use prefilled syringe |
| Prescription Status | Prescription only |
| Atc Code | H01CC01 |
| Country Of Approval | India |
| Contraindications | Known hypersensitivity to ganirelix or similar compounds |
| Excipients | Acetic acid, mannitol, water for injection |
| Color | Clear and colorless solution |
As an accredited GANILEVER® Prefilled Syringe Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | GANILEVER® Prefilled Syringe Inj. is packaged in a sterile box containing 1mL x 1 prefilled syringe, secured with necessary labeling. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for GANILEVER® Prefilled Syringe Inj.: 20,000 cartons securely packed, temperature-controlled, with pallets for efficient handling and transportation. |
| Shipping | GANILEVER® Prefilled Syringe Inj. is shipped in temperature-controlled packaging to maintain product stability and ensure quality. The syringes are securely packed to prevent breakage and contamination. Shipping documentation includes handling instructions and regulatory compliance. Delivery is prompt, with tracking provided for real-time monitoring until safe arrival at the destination. |
| Storage | **GANILEVER® Prefilled Syringe Inj.** should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Keep the syringe in the original packaging to protect it from light. Do not freeze. Protect from excessive heat and avoid shaking. Keep out of reach of children. Do not use after the expiration date indicated on the packaging. |
| Shelf Life | GANILEVER® Prefilled Syringe Inj. has a shelf life of 36 months when stored below 25°C, protected from light. |
As a dedicated manufacturer, we supply GANILEVER® Prefilled Syringe Inj. for a range of highly regulated industrial sectors. Our formulation addresses specific technical requirements for injectable formats where sterility, precise dosing, and compliance with international standards are critical. Below, we detail several typical downstream industrial uses.
Pharmaceutical companies utilize this sterile prefilled syringe in the packaging stage for monoclonal antibodies, vaccines, and peptide-based therapies. The product provides a ready-to-administer platform that supports stringent aseptic filling and final packaging lines. Our clients integrate validated batches into automated filling and plunger assembly lines, ensuring patient safety, unit-dose reliability, and streamlined regulatory submission for parenteral products under real-world GMP constraints.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Central hospital pharmacies package emergency drugs, such as atropine, epinephrine, or naloxone, using prefilled sterile syringes for clinical crash carts and ambulatory systems. The format reduces risk of dosing error and enables rapid deployment in critical care environments. Facility QCs include sterility assurance, container closure integrity, and plunger glide force for immediate patient use in high-stress settings where reconstitution or manual drawing is not feasible.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Veterinary pharmaceutical manufacturers use such prefilled syringes for controlled administration of vaccines and therapeutic injectables in livestock and companion animals. These syringes provide pre-metered, sterile dosage forms that comply with animal health legal regulations. Consistent production batches and validated sterility cycles ensure reliable product performance for field veterinarians and animal hospitals managing both large-volume livestock campaigns and high-value pet therapies.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Combination drug-device manufacturers assemble specialized injection sets, autoinjectors, and pen systems that incorporate prefilled sterile syringes as essential core components. Production processes include validated in-line assembly, device-pressure testing, and electronics integration for tracked delivery systems. Finished goods undergo full ISO 13485 device dossier submission and post-market surveillance as required by European and North American device authorities.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive GANILEVER® Prefilled Syringe Inj. prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618018036652
Email: sales6@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
In the pharmaceutical industry, a prefilled syringe stands for more than just a delivery device. It's a pledge to patient safety, quality, and precise dosing. GANILEVER® Prefilled Syringe Inj. comes from years of focused engineering in our own sterile filling lines, guided by careful collaboration with clinicians and partners who rely on consistent supply and reproducibility. Feedback from hospitals taught us what works in clinical settings and where frustrations often lie, paving the way for actual solutions. Every syringe unit leaves our facility with integrity and clarity, because trust in medication begins before the product even arrives at the bedside.
Our prefilled syringe brings together medical-grade borosilicate glass, precision-molded plungers, and carefully selected elastomer stoppers to anchor stability from end to end. Models in the product line serve both low and higher dose applications, supporting injection volumes ranging from 0.5 mL up to 5 mL. The plunger and stopper have been tested repeatedly for extractables and leachables across seasonal changes, ensuring every lot matches the documented shelf-life and storage profile.
Traditional vial-and-syringe combinations face multiple contamination risks: open handling, repeat air exposure, and potential for incorrect withdrawals. With GANILEVER® Prefilled Syringe, we've locked in sterility up front, with terminal sterilization or aseptic filling, then sealed each barrel with a tamper-evident cap. The fixed needle models use ultra-smooth stainless steel chosen for biocompatibility and anti-stick performance, while detachable needle models suit clinics that follow switchable gauge protocols. Needleless options simplify disposal processes for high-volume facilities, following feedback from urban emergency departments confronting needle stick incidents.
Quality for us starts in small ways, such as incoming glass tube selection and frequent weight checks throughout assembly. No two lots pass into filling lines without a multi-point physical inspection. To us, it’s critical that barrels aren’t just clear—each must resist microfractures and surface defects, even under harsh shipment conditions. We still recall frustrating shipments from overseas glass providers ten years ago, where one small inclusion in the glass led to major recalls—since then, every melt batch is certified and batch records archived for five years. Suitability with a range of drug formulations was not an afterthought; lyophilized biologics, viscous lipophilic solutions, and saline-based therapies each undergo trial fills to observe stiction and glide force in real time.
Our in-house lubricants never touch the fluid path, because certain silicone residues cause issues with protein-based drugs. Instead, the plungers use an inert polymer blend that doesn’t initiate aggregation or clogging, even after years in cold chain. For medications requiring high clarity—such as hyaluronic acid or clear peptides—GANILEVER® Syringe glass grades reach well below standard USP parameters for visible particulates. Labels use ink validated for alcohol-resistant wipe-downs, following direct hospital feedback that smudged labeling wastes precious prep time.
A good syringe doesn’t just store and deliver; it reduces unintentional waste and dosing errors. Our filling heads use volume-controlled peristaltic systems, so each unit delivers within 2% of the target—this means less re-testing for batch release and less risk of under-dosing. Out of every hundred thousand syringes, internal holds for underfills remain below industry averages (audited monthly), preventing downstream issues during clinical audits and regulatory inspections. Our teams see firsthand how unplanned batch rejections force stressful overtime and dent confidence in the whole supply chain.
With a focus on both single-use and multi-dose scenarios, GANILEVER® now includes safety-engineered shields. Several regional hospitals have reduced needle-stick injuries after switching from standard to safety-shielded versions. Our engineers modified shield deployment tension following a year of partnership with providers who tracked near-miss accident metrics. The shield system now snaps smoothly with one hand, reducing sharps injuries in fast-paced environments. This change alone drew thanks from nursing teams who felt ignored by designs that claim “user-friendliness” but don’t actually stand up to real clinical workloads.
Every GANILEVER® prefilled batch ships with scannable lot numbers, integrated with the serialized traceability system in use at our fill-finish plant. Practitioners can instantly confirm batch origin and expiration using widely available hospital inventory apps. Some manufacturers treat lot tracking as a regulatory hassle; for us, it’s a practical way to keep lines of communication open across the lifespan of the product. A case of GANILEVER® can be traced from line worker to end-user, with electronic records ready for recall audits or just-in-time distribution adjustments.
Thorough lot release documentation, including extractables, particle analysis, and pressure testing, is on file for all major markets. This documentation isn’t just for certifications. It allows pharmacies and purchasing teams to make faster approval decisions without chasing PDF certificates from third-party aggregators. Some competing syringes leave hospitals waiting days or weeks for full documentation. By choosing vertical integration in our own facility, we’ve trimmed this waiting time so real-world users get prompt, detailed assurances on every box.
Behind every GANILEVER® syringe, plant operators and pharmacy technicians review cycle times, fill consistency, and post-fill inspection images daily. Feedback comes straight from those hands-on roles, not just executive reports. Workflow tweaks—sometimes as simple as changing a material feed angle or a box liner—come from listening to the packers and machinists who know exactly where efficiency breaks down in real time.
We've seen that during peak flu seasons, distributors' backrooms get choked with packaging from legacy products that don’t stack well or require secondary reboxing. GANILEVER® cartons are designed to fit evenly on European and US palettes, with minimal exterior void, allowing for quick, damage-free loading and inventory checks. At first, this shift might seem small, but warehouse teams send regular thanks because it means fewer injuries during heavy cycles and easier auditing by inventory managers. Sometimes real progress shows up in the hands and backs of those often overlooked.
We've watched competitors launch prefilled syringe lines with splashy claims but hidden supply chain vulnerabilities. Some trade on imported barrels, others batch-fill through third-party contractors with little oversight. From our experience, this creates uneven product and trouble during regulatory sprints. GANILEVER® remains one of the few branded lines produced entirely in a single facility—glass, plungers, stoppers, and fill lines all under one roof. Our in-process controls have meant we pass international audits with fewer corrective actions. Hospital procurement teams have shared frustration after switching to lower-cost, high-variation syringes, quickly returning to our door after multiple incident reports related to leakage, glass fragility, or inconsistent labeling.
It doesn’t escape us that the prefilled market grows more crowded each year, with many choices squeezed by pricing games or niche formats. Our approach isn’t to chase the lowest cost per unit. Instead, we choose to continuously invest in machine improvements and new fill verification software. This translates to longer shelf-lives, more accurate dosing, and fewer headaches for pharmacists. Companies boasting one-off innovations—magnetic plungers, thermal-responsive stoppers—often introduce variables that supply chains are not yet equipped to track at scale. By focusing on consistent, proven improvements instead of novelty, GANILEVER® has avoided many of the disruptions that beset wider industry rollouts.
Sterile injectable products demand ongoing vigilance against both visible and sub-visible particles. Our production team runs daily checks using light-scattering technology and human inspectors trained to spot the smallest anomalies. Automated detection never completely replaces sharp human observation—plant supervisors run monthly workshops on how to reduce eye fatigue and report near-misses without hesitation. This culture grows from early missteps—a recall in the past taught us that speed and trust hinge on the forthrightness of each shift operator, not just final QC sign-off.
Shipping remains a critical issue. Even with robust primary packaging, transport stresses can introduce defects. We've invested in drop tests and vibration testing chambers, replicating worst-case scenarios from air, sea, and ground freight. Urban hospitals in seismic regions once reported sporadic glass cracking in supplies from another manufacturer. After careful data review, we switched all GANILEVER® shipments in specific geographies to enhanced shippers with integrated shock absorbers.
Drug compatibility stands as a stubborn challenge. Biopharmaceutical formulations can degrade or bind to barrel walls. The R&D team runs ongoing interaction studies using our own plasma and protein-based compounds. We learned from a trial involving an experimental peptide that even small polymer residues can reduce potency over months at 2ºC. That insight led us to swap out the lubricant blend entirely in select SKUs—dramatically reducing complaint rates and extending recommended shelf-lives. Direct conversations with hospital pharmacists, who recall full fridge drawers of waste due to incompatibility, shape every improvement.
Entering new markets brings a flood of regulatory documentation and shifting shelf-life and composition requirements year after year. GANILEVER® keeps prepared master files for major regulatory authorities and runs stability testing one year ahead of market launches. A dedicated compliance team meets quarterly with regional advisers to spot upcoming changes, reducing the chance of production halts over paperwork delays. We faced delays in one country when a minor label font change was flagged at customs. Ever since, our regulatory files get triple-reviewed, and on-site label presses now update runs the day new specs are released. This direct response avoids costly on-hold inventory and keeps hospital shelves stocked smoothly.
As a direct supplier who has stood in front of ministry auditors and health inspectors ourselves, we prefer over-preparation to scrambling for compliance. Hospital purchasing teams, caregivers, and patients shouldn’t run risks due to upstream oversight gaps. Our latest digital documentation suites now include lot-level photographic evidence, making past batch audits faster for authorities and building trust in fast-developing regions with new regulatory infrastructure.
Needle-associated injuries and access barriers persist wherever injectable products are handled, especially in community clinics and resource-stretched hospitals. GANILEVER® worked with partners in rural and emergency settings to create clear, color-coded indicators and improved tactile grips to suit gloved and ungloved hands—ensuring confidence for new and veteran staff under stress. Visually impaired users repeatedly struggle with standard print fonts; in response, our external packaging shifted to include tactile orientation markers, with user feedback informing every iteration.
Accessible design expands beyond print and touch. Syringes in the GANILEVER® line reach up to -20ºC cold-chain compatibility, supporting public health campaigns where refrigeration falls short. Relief programs in remote regions require products that tolerate logistical setbacks, unplanned temperature excursions, and rough field handling. In practice, clinicians relay stories of products held at border facilities or tucked into rural supply trucks for days past expected timelines. Through stability studies simulating actual logistics, GANILEVER® aims to protect both product and patient, cutting spoilage and extending critical access where the need is greatest.
We recognize that no factory line ever runs perfectly—and real learning comes from sharing, not hiding, near misses and mistake trends. Within GANILEVER®, a suggestion box sits physically and digitally at every shift, used and respected by line staff and lead engineers alike. Several improvements—enhanced edge chamfering on glass, new carton opens, nozzle-tip dust covers—came from these anonymous notes, not outside consultants. The culture owes its resilience to direct, ongoing feedback loops between those who make and those who use the product every day. Industry standards may set the foundation, but day-to-day practical challenges, faced head on, drive lasting improvements.
As medicine moves toward more individualized and high-potency therapies, demand surges for sterile, predictable delivery systems. We see frequent requests for smaller, nested tub formats, higher viscosity compatibility, and longer shelf-stability—all areas actively under development within GANILEVER®. Each new challenge reinforces our conviction that continuous investment in infrastructure, people, and data tracking maximizes both patient safety and the efficiency of care delivery. From daily QC rounds to direct hospital conversations, every improvement in GANILEVER® Prefilled Syringe Inj. begins with showing up, listening, and translating that learning back into robust, everyday solutions.
Drug delivery, patient safety, and line efficiency cannot be left to chance. From our experience, the only sustainable way forward is making each production day count, learning from every hand that touches the product—on the line, in pharmacies, and at the bedside. That commitment stays central to everything behind the GANILEVER® name.